IMC Chicago’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.76M Buy
16,600
+9,600
+137% +$1.71M ﹤0.01% 2409
2026
Q1
$1.21M Sell
7,000
-3,200
-31% -$593K ﹤0.01% 3076
2025
Q4
$2.03M Sell
10,200
-100
-1% -$18.1K ﹤0.01% 2404
2025
Q3
$1.61M Sell
10,300
-1,800
-15% -$286K ﹤0.01% 2386
2025
Q2
$1.84M Buy
+12,100
New +$1.61M ﹤0.01% 2072

Other funds holding CRL

IMC Chicago's CRL Position: Q2 2026 in Review

IMC Chicago sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 7,293 shares — an estimated $1.3M sold.

IMC Chicago first reported a position in CRL in Q1 2026 and held it in 1 quarter. The position peaked at $1.26M in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • IMC Chicago reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 7,293 Charles River Laboratories shares in Q2 2026, an estimated $1.3M.
  • IMC Chicago first reported a position in Charles River Laboratories in Q1 2026 and held it in 1 quarter.
  • IMC Chicago's Charles River Laboratories position peaked at $1.26M in Q1 2026.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.